STOCK TITAN

Vanda Pharmaceuticals Inc. (VNDA) Net Income by Year

VNDA

Vanda Pharmaceuticals Inc. reported a net loss of $220.5M in fiscal year 2025. This represents a decrease of 1066.7% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to a $274.9M net loss. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Vanda Pharmaceuticals Inc. has filed alongside them.

FY2025 annual
Net Income -$220.5M
YoY -1066.7%
Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

VNDA Net Income by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricTTMFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-KFY1910-KFY1810-KFY1710-KFY1610-KFY1510-KFY1410-KFY1310-KFY1210-KFY1110-K
Net Income-$274.9M-$220.5M-1066.7%-$18.9M-856.0%$2.5M-60.3%$6.3M-81.0%$33.2M+42.3%$23.3M-79.8%$115.6M+358.4%$25.2M+261.9%-$15.6M+13.6%-$18.0M+54.8%-$39.9M-297.5%$20.2M+195.9%-$21.1M+26.4%-$28.6M-192.0%-$9.8M

TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.

VNDA Net Income by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-KQ3'2310-Q
Net Income-$62.5M-129.8%-$48.6M-64.7%-$141.2M-2774.9%-$22.6M-324.2%-$27.2M-502.2%-$29.5M-611.4%-$4.9M-103.9%-$5.3M-3986.1%-$4.5M-397.2%-$4.1M-227.5%-$2.4M-135.0%$137K-95.8%

What net income means

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.

More Vanda Pharmaceuticals Inc. financials

Frequently Asked Questions

What was Vanda Pharmaceuticals Inc.'s net income in fiscal year 2025?

Vanda Pharmaceuticals Inc. reported a net loss of $220.5M in fiscal year 2025.

How fast is Vanda Pharmaceuticals Inc.'s net income growing?

Vanda Pharmaceuticals Inc. (VNDA) net income fell by 1066.7% year over year, from -$18.9M to -$220.5M in fiscal year 2025.

What is Vanda Pharmaceuticals Inc.'s net income over the last twelve months?

Vanda Pharmaceuticals Inc. (VNDA) reported a $274.9M net loss over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.

Across the 15 fiscal years this page covers, Vanda Pharmaceuticals Inc. (VNDA) net income went from -$9.8M in fiscal year 2011 to -$220.5M in fiscal year 2025.

Vanda Pharmaceuticals Inc. (VNDA) reported -$62.5M in net income in Q2 2026. This represents a decrease of 129.8% from the same quarter a year earlier.

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what Vanda Pharmaceuticals Inc. (VNDA) reported on that line in every period on record.